U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Breast Lymphoma

MedGen UID:
1627359
•Concept ID:
C4527333
•
Neoplastic Process

Definition

Breast lymphoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Breast Lymphoma

Professional guidelines

PubMed

Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216
Aprepitant for the Treatment of Chronic Refractory Pruritus.
He A, Alhariri JM, Sweren RJ, Kwatra MM, Kwatra SG
Biomed Res Int 2017;2017:4790810. Epub 2017 Sep 19 doi: 10.1155/2017/4790810. PMID: 29057261Free PMC Article
Management of Anaplastic Large Cell Lymphoma.
Chihara D, Fanale MA
Hematol Oncol Clin North Am 2017 Apr;31(2):209-222. doi: 10.1016/j.hoc.2016.11.001. PMID: 28340874

Recent clinical studies

Etiology

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN
J Clin Oncol 2023 Aug 20;41(24):3988-3997. Epub 2023 May 16 doi: 10.1200/JCO.23.00562. PMID: 37192437Free PMC Article
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G
Lancet Haematol 2022 Oct;9(10):e756-e765. Epub 2022 Sep 2 doi: 10.1016/S2352-3026(22)00216-2. PMID: 36063832
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM
J Clin Oncol 2021 Sep 1;39(25):2768-2778. Epub 2021 May 27 doi: 10.1200/JCO.20.03736. PMID: 34043428Free PMC Article
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216

Diagnosis

Obesity and multiple myeloma: Emerging mechanisms and perspectives.
Tentolouris A, Ntanasis-Stathopoulos I, Terpos E
Semin Cancer Biol 2023 Jul;92:45-60. Epub 2023 Apr 6 doi: 10.1016/j.semcancer.2023.04.003. PMID: 37030643
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM
J Clin Oncol 2021 Sep 1;39(25):2768-2778. Epub 2021 May 27 doi: 10.1200/JCO.20.03736. PMID: 34043428Free PMC Article
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216
Early lymphoid lesions: conceptual, diagnostic and clinical challenges.
Ganapathi KA, Pittaluga S, Odejide OO, Freedman AS, Jaffe ES
Haematologica 2014 Sep;99(9):1421-32. doi: 10.3324/haematol.2014.107938. PMID: 25176983Free PMC Article
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H
Med Res Rev 2014 Mar;34(2):280-300. Epub 2013 May 21 doi: 10.1002/med.21288. PMID: 23696246

Therapy

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM
J Clin Oncol 2021 Sep 1;39(25):2768-2778. Epub 2021 May 27 doi: 10.1200/JCO.20.03736. PMID: 34043428Free PMC Article
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M
Int J Mol Med 2020 Feb;45(2):279-297. Epub 2019 Dec 4 doi: 10.3892/ijmm.2019.4418. PMID: 31894255Free PMC Article
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H
Med Res Rev 2014 Mar;34(2):280-300. Epub 2013 May 21 doi: 10.1002/med.21288. PMID: 23696246

Prognosis

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN
J Clin Oncol 2023 Aug 20;41(24):3988-3997. Epub 2023 May 16 doi: 10.1200/JCO.23.00562. PMID: 37192437Free PMC Article
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM
J Clin Oncol 2021 Sep 1;39(25):2768-2778. Epub 2021 May 27 doi: 10.1200/JCO.20.03736. PMID: 34043428Free PMC Article
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216
Adult T-cell leukemia-lymphoma.
Tsukasaki K
Hematology 2012 Apr;17 Suppl 1:S32-5. doi: 10.1179/102453312X13336169155330. PMID: 22507774

Clinical prediction guides

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN
J Clin Oncol 2023 Aug 20;41(24):3988-3997. Epub 2023 May 16 doi: 10.1200/JCO.23.00562. PMID: 37192437Free PMC Article
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A
Clin Cancer Res 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811. PMID: 35583555Free PMC Article
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216
rHuEPO and treatment outcomes: the clinical experience.
Hudis CA, Van Belle S, Chang J, Muenstedt K
Oncologist 2004;9 Suppl 5:55-69. doi: 10.1634/theoncologist.9-90005-55. PMID: 15591423

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...